Close Menu

NEW YORK – Clinical research organization ProSciento announced Thursday a partnership with biomarker technology firm Nordic Bioscience to identify translational biomarkers for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.